Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 16

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1A
Chunk 16
---
 from any errors in the use, manufacture, design, labelling or performance of its products,
including any false-positive or false-negative results.

In addition,
other companies are developing competing cancer detection tests and technologies focused on improving cancer care with cancer detection
tests and post-diagnostic products. If any tests marketed or being developed by Renovaro Cube’s competitors that are similar
to its products do not perform in accordance with expectations or cause harm or injury to patients, such failure to perform, harm or injury
may result in lower confidence in early disease detection and post-diagnosis tests in general, which could potentially adversely
affect confidence in Renovaro Cube’s products and result in an adverse impact on its operating results and reputation.

BioSymetrics
does not currently have a similar diagnostic product, but if developing a similar product the same risks would apply.

If Renovaro Cube’s
or BioSymetrics’ facilities or those of its third-party collaborators become inoperable, their ability to provide its
products will be significantly impaired and its business will be harmed.

Renovaro
Cube and BioSymetrics rely on third-party collaborators, consultants, contractors, vendors, suppliers and service providers.
The facilities of these partners could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods,
tornadoes, hurricanes, fires, extreme weather conditions, medical epidemics, pandemics, global conflict, war and other natural or man-made disasters
or business interruptions. In addition, they may be affected by government shutdowns, changes to applicable laws, regulations and policies,
or withdrawn funding. The occurrence of any of these business disruptions could seriously harm their ability to complete their contracted
services to Renovaro Cube or BioSymetrics, which may adversely impact their operations and financial condition.

Renovaro
Cube’s and BioSymetrics’ business and results of operations will suffer if it fails to compete effectively.

The testing
and diagnostic products industry is intensely competitive. Renovaro Cube has competitors both in Europe and abroad, including Grail, Inc.,
Exact Sciences Corporation, Freenome, Inc. and Thrive Earlier Detection Corp., that have stated that they are developing tests designed
to detect cancer. Similarly, there are companies with comparable and possibly competing offerings to BioSymetrics, including Recursion
Pharma, insitro, and In Silico Medicine. Each of these potential competitors have, or may have, substantially greater